MedTrace Logo

A Study to Evaluate the Efficacy, Safety and Tolerability of MIV-711 in Osteoarthritis Patients

NCT02705625 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 244

Last updated 2019-06-17

Study results available
· View outcomes & findings →

Summary

This is a multicentre, randomised, placebo-controlled, double-blind, three-arm parallel, Phase IIa study to evaluate the efficacy, safety and tolerability of MIV-711 in patients with knee osteoarthritis (OA).

Conditions

  • Osteoarthritis, Knee

Interventions

DRUG

MIV-711

MIV-711 administered orally once daily

DRUG

Placebo

Placebo manufactured to mimic MIV-711 capsule.

Sponsors & Collaborators

  • Medivir

    lead INDUSTRY

Principal Investigators

  • Philip Conaghan, Professor · Leeds Institute of Rheumatic and Musculoskeletal Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-28
Primary Completion
2017-05-23
Completion
2017-05-23

Countries

  • Bulgaria
  • Georgia
  • Germany
  • Moldova
  • Romania
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02705625 on ClinicalTrials.gov